{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:05:48Z","timestamp":1767139548360,"version":"build-2238731810"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00347-024-02177-4","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:25:47Z","timestamp":1737991547000},"page":"315-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Augeninnendruckentgleisung, Hyph\u00e4ma und Uveitis bei chronischer lymphatischer Leuk\u00e4mie unter Ibrutinib-Therapie","Intraocular pressure rise, hyphema and uveitis in chronic lymphocytic leukemia undergoing ibrutinib treatment"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9350-2645","authenticated-orcid":false,"given":"Abdelrahman","family":"Assaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidan","family":"Aghayeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines M.","family":"Lanzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"5","key":"2177_CR1","first-page":"3489","volume":"13","author":"CP Chaulagain","year":"2020","unstructured":"Chaulagain\u00a0CP et\u00a0al (2020) Progressive multifocal leukoencephalopathy (PML) after first-line, single agent ibrutinib therapy in a\u00a0patient with chronic lymphocytic leukemia (CLL): a\u00a0case report and literature review. Int J Clin Exp Med 13(5):3489\u20133493","journal-title":"Int J Clin Exp Med"},{"key":"2177_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-3-642-54490-3_17","volume":"201","author":"MA Schwarzbich","year":"2014","unstructured":"Schwarzbich\u00a0MA, Witzens-Harig\u00a0M (2014) Ibrutinib. Recent Results Cancer Res 201:259\u2013267","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"2177_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst\u00a0B et\u00a0al (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(1):23\u201333","journal-title":"Ann Oncol"},{"key":"2177_CR4","doi-asserted-by":"crossref","unstructured":"Allouchery M et\u00a0al (2021) Safety profile of Ibrutinib: an analysis of the WHO pharmacovigilance database. Front Pharmacol: 2957","DOI":"10.3389\/fphar.2021.769315"},{"key":"2177_CR5","first-page":"101300","volume":"25","author":"ZK Chiu","year":"2022","unstructured":"Chiu\u00a0ZK, Goh\u00a0JK, Ling\u00a0C, Lin\u00a0ML, Hall\u00a0AJ (2022) Ibrutinib-related uveitis: a\u00a0case series. Am J Ophthalmol 25:101300","journal-title":"Am J Ophthalmol"},{"issue":"15","key":"2177_CR6","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky\u00a0JA, Beckwith\u00a0KA, Natarajan\u00a0G et\u00a0al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a\u00a0Th1-selective pressure in T lymphocytes. Blood 122(15):2539\u20132549","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s00347-025-02208-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000}}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02177-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:43:15Z","timestamp":1744134195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02177-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02177-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Originalversion dieses Beitrags wurde korrigiert: die Legenden der Abbildungen 2 und 3 wurden versehentlich vertauscht.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00347-025-02208-8","URL":"https:\/\/doi.org\/10.1007\/s00347-025-02208-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Assaf, F.\u00a0Aghayeva und I.M.\u00a0Lanzl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}